Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination

Journal of the National Cancer Institute

Volumn 92, Issue 16, 2000, Pages 1336-1344

  Kammula, Udai S ^a   Marincola, Francesco M ^a,b   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOKINE; EPITOPE;

ANALYTIC METHOD; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; MELANOMA; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SECRETION; SENSITIZATION;

EID: 0034674904     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.16.1336     Document Type: Article

References (25)

1. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens
2. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
3. Immunization against epitopes in the human melanoma antigen gp 100 following patient immunization with synthetic peptides
4. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine
5. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
6. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
7. Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides
8. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence for in vivo priming by tumor cells
9. Phenotypic analysis of antigen-specific T lymphocytes
10. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
11. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay
12. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
13. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
14. Real time quantitative PCR
15. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood
16. Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: Relevance for epitope specific vaccination protocols
17. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides
18. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
19. Cancer vaccines based on the identification of genes encoding cancer regression antigens
20. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
21. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
22. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
23. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
24. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo
25. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice